Historical Valuation
Journey Medical Corp (DERM) is now in the Fair zone, suggesting that its current forward PS ratio of 2.16 is considered Fairly compared with the five-year average of 16.15. The fair price of Journey Medical Corp (DERM) is between 4.12 to 7.44 according to relative valuation methord.
Relative Value
Fair Zone
4.12-7.44
Current Price：7.27
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Journey Medical Corp (DERM) has a current Price-to-Book (P/B) ratio of 7.59. Compared to its 3-year average P/B ratio of 707.31 , the current P/B ratio is approximately -98.93% higher. Relative to its 5-year average P/B ratio of 508.51, the current P/B ratio is about -98.51% higher. Journey Medical Corp (DERM) has a Forward Free Cash Flow (FCF) yield of approximately -1.94%. Compared to its 3-year average FCF yield of -11.76%, the current FCF yield is approximately -83.46% lower. Relative to its 5-year average FCF yield of -11.18% , the current FCF yield is about -82.60% lower.
P/B
Median3y
707.31
Median5y
508.51
FCF Yield
Median3y
-11.76
Median5y
-11.18
Competitors Valuation Multiple
AI Analysis for DERM
The average P/S ratio for DERM competitors is 3.07, providing a benchmark for relative valuation. Journey Medical Corp Corp (DERM.O) exhibits a P/S ratio of 2.16, which is -29.73% above the industry average. Given its robust revenue growth of 20.52%, this premium appears sustainable.
Performance Decomposition
AI Analysis for DERM
1Y
3Y
5Y
Market capitalization of DERM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DERM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is DERM currently overvalued or undervalued?
Journey Medical Corp (DERM) is now in the Fair zone, suggesting that its current forward PS ratio of 2.16 is considered Fairly compared with the five-year average of 16.15. The fair price of Journey Medical Corp (DERM) is between 4.12 to 7.44 according to relative valuation methord.
What is Journey Medical Corp (DERM) fair value?
DERM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Journey Medical Corp (DERM) is between 4.12 to 7.44 according to relative valuation methord.
How does DERM's valuation metrics compare to the industry average?
The average P/S ratio for DERM's competitors is 3.07, providing a benchmark for relative valuation. Journey Medical Corp Corp (DERM) exhibits a P/S ratio of 2.16, which is -29.73% above the industry average. Given its robust revenue growth of 20.52%, this premium appears sustainable.
What is the current P/B ratio for Journey Medical Corp (DERM) as of Jan 10 2026?
As of Jan 10 2026, Journey Medical Corp (DERM) has a P/B ratio of 7.59. This indicates that the market values DERM at 7.59 times its book value.
What is the current FCF Yield for Journey Medical Corp (DERM) as of Jan 10 2026?
As of Jan 10 2026, Journey Medical Corp (DERM) has a FCF Yield of -1.94%. This means that for every dollar of Journey Medical Corp’s market capitalization, the company generates -1.94 cents in free cash flow.
What is the current Forward P/E ratio for Journey Medical Corp (DERM) as of Jan 10 2026?
As of Jan 10 2026, Journey Medical Corp (DERM) has a Forward P/E ratio of 59.60. This means the market is willing to pay $59.60 for every dollar of Journey Medical Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Journey Medical Corp (DERM) as of Jan 10 2026?
As of Jan 10 2026, Journey Medical Corp (DERM) has a Forward P/S ratio of 2.16. This means the market is valuing DERM at $2.16 for every dollar of expected revenue over the next 12 months.